Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

iTeos Therapeutics S.A.. (12/7/15). "Press Release: iTeos Therapeutics Awarded EUR 3 Million in Funding a New Drug Discovery Program for Cancer Immunotherapy". Gosselies.

Region Region Wallonia (region)
  Country Belgium
Organisations Organisation iTeos Therapeutics S.A.
  Organisation 2 Wallonia (govt region)
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 business development (state/region)
Persons Person Detheux, Michel (iTeos Therapeutics 201205 CEO + Co-founder)
  Person 2 Quéva, Christophe (iTeos Therapeutics 201512 CSO)
     


Walloon Government supports the development of iTeos proprietary pipeline to develop novel therapeutics targeting the immune tumor micro-environment


iTeos Therapeutics SA, the drug discovery company for immunomodulators, announced that it has received a €2.94 million non-dilutive funding from the Walloon Region of Belgium to expand its preclinical drug discovery pipeline targeting new immunotherapies for the tumor micro-environment.

“This grant will allow us to expand our proprietary pipeline by adding a program to develop small molecule inhibitors for a target involved in T cell anergy”. said Christophe Quéva Ph.D., chief scientific officer of iTeos. “It will complement our growing portfolio of small molecules and antibody approaches aimed at stimulating certain immune responses against cancers.”

"We are very pleased to continue to receive strong support for our preclinical research from the Walloon Region. In parallel to our strategic collaboration with Pfizer, which was announced in 2014, we are expanding the Company’s drug candidate pipeline where such grant support is pivotal for our research efforts to discover our own diversified and innovative set of drug candidate programs." said Michel Detheux Ph.D., chief executive officer of iTeos.


About iTeos Therapeutics SA

Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), has built a discovery platform to identify therapeutics targeting the immune tumor micro-environment to optimize cancer immunotherapy. iTeos combines unparalleled expertise in tumor immunology, cancer immunotherapy and drug discovery. The company entered into a strategic collaboration with Pfizer in December 2014. iTeos is developing partnerships with charities, top-tier academic and industrial partners to develop new programs. iTeos is supported by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development).

   
Record changed: 2017-07-30

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for iTeos Therapeutics S.A.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px